Scarica l'app Stockscreener
2.4291
1.26%
0.0391
Precedente Chiudi:
$2.39
Aprire:
$2.4
Volume 24 ore:
452.77K
Relative Volume:
0.09
Capitalizzazione di mercato:
$195.10M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-121.45
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+1.26%
1M Prestazione:
+12.04%
6M Prestazione:
+178.87%
1 anno Prestazione:
+68.06%
Intervallo 1D:
$2.36
$2.465
Intervallo di 1 settimana:
$2.315
$2.50
Portata 52W:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.42 | 378.11M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.69 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.91 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.40 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.84 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.02 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
What drives CytomX Therapeutics Inc. stock priceFree Stock Movement Tracking - Autocar Professional
CytomX Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
What analysts say about CytomX Therapeutics Inc. stockFree Trading Strategy Suggestions - jammulinksnews.com
Is CytomX Therapeutics Inc. a good long term investmentFree Stock Market Return Analysis - Autocar Professional
Why CytomX Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
What makes CytomX Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
How CytomX Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser
The Future of Allogene Therapeutics Inc: Analyzing ALLO - investchronicle.com
Pliant Therapeutics Inc (PLRX) Stock: Navigating a Year of Volatility - investchronicle.com
CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Do CytomX Therapeutics' (NASDAQ:CTMX) Earnings Warrant Your Attention? - Yahoo Finance
CytomX Q2 2025 presentation slides: CX-2051 shows promising Phase 1 results in CRC By Investing.com - Investing.com South Africa
CytomX Q2 2025 presentation slides: CX-2051 shows promising Phase 1 results in CRC - Investing.com
Certain Pre-Funded warrants of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JUN-2025. - MarketScreener
CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView
CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks
Stocks in play: Roots Corp. - The Globe and Mail
Two Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail
GoldMining Announces Closing of Flow-Through Financing and Commences Exploration at Yellowknife Gold Project - The Globe and Mail
Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail
Northern Trust Corp Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue By Investing.com - Investing.com UK
BMO Lowers Fees on Asset Allocation ETFs to Deliver Greater Value to Investors - The Globe and Mail
Millennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com South Africa
CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia
CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times
CytomX Shares Skyrocket: What’s Next? - StocksToTrade
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytomx Therapeutics Inc Azioni (CTMX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
| Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
| McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
| McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
| McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
4.15%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):